KKR, Flerie partner to form pharma services platform and invest in companies

KKR announced, in partnership with Flerie, the formation of a new global pharma services platform, Frontier Biosolutions, which will invest in a portfolio of companies focused on specialized pharmaceutical services to advanced therapeutics customers. Frontier will invest in differentiated scientific capabilities and proprietary technology platforms that address critical bottlenecks in the development and manufacturing of advanced therapeutics. Industry veteran and co-investor Thomas Eldered will serve as Frontier’s executive chairman, bringing more than 34 years of senior management expertise to the management board and drawing on his experience as co-founder of Recipharm and as a life sciences investor at Flerie. As the platform’s foundational investment, funds managed by KKR and Flerie, through Frontier, have invested in Munich-based Coriolis Pharma, a company in formulation research and development, analytical services and non-GMP manufacturing of biologics and cell and gene therapy products. KKR’s investment will enable Coriolis’ continued expansion, especially into the fast-growing cell and gene therapy segment and will expand its range of services offered to customers globally.